Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities
- 1 January 2021
- book chapter
- Published by Elsevier
- Vol. 365, 1-69
Abstract
No abstract availableKeywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro (21267)
- Ministero dell'Università e della Ricerca (PRIN-2017WXR7ZT)
This publication has 255 references indexed in Scilit:
- Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international studyLeukemia, 2013
- MPN patients harbor recurrent truncating mutations in transcription factor NF-E2Journal of Experimental Medicine, 2013
- The JAK2 V617F mutation in patients with cerebral venous thrombosisJournal of Thrombosis and Haemostasis, 2012
- JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatmentTherapeutic Advances in Hematology, 2010
- Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patientsLeukemia, 2010
- IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosisLeukemia, 2010
- Calreticulin: non‐endoplasmic reticulum functions in physiology and diseaseThe FASEB Journal, 2009
- Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disordersJournal of Thrombosis and Haemostasis, 2007
- JAK2Exon 12 Mutations in Polycythemia Vera and Idiopathic ErythrocytosisNew England Journal of Medicine, 2007
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005